Hygeia Healthcare Holdings Co (STU:50I) Research & Development: €0.0 Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:50I Hygeia Healthcare Holdings Co Ltd STU:50I
74 GF Score
Price €1.06
GF Value €2.43
Valuation Possible Value Trap
! 7 Warning Signs
View Full Analysis

What is Hygeia Healthcare Holdings Co Research & Development?

Hygeia Healthcare Holdings Co STU:50I -2.75% 74 Research & Development is €0.0 Mil as of Dec. 2025. GuruFocus rates STU:50I with a GF Score™ of 74/100 and a GF Value™ of €2.43 (Possible Value Trap). The stock has 7 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Hygeia Healthcare Holdings Co's Research & Development for the six months ended in Dec. 2025 was €0.0 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 was €0.0 Mil.

Hygeia Healthcare Holdings Co  (STU:50I) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Hygeia Healthcare Holdings Co Research & Development Related Terms

Hygeia Healthcare Holdings Co Research & Development Historical Data

* Premium members only.

The historical data trend for Hygeia Healthcare Holdings Co's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Hygeia Healthcare Holdings Co Research & Development Chart

Hygeia Healthcare Holdings Co Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only 0.00 0.00 0.00 0.00 0.00

Hygeia Healthcare Holdings Co Semi-Annual Data
Dec17 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25 Jun26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
STU:50I
74GF Score
Hygeia Healthcare Holdings Co Ltd STU:50I
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Hygeia Healthcare Holdings Co Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was €0.0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of €0.0 Mil mean?
Hygeia Healthcare Holdings Co (STU:50I) has a Research & Development of €0.0 Mil as of Dec. 2025. Research and development expense is the total cost for research and development activities. View historical data on Hygeia Healthcare Holdings Co and its competitors.
Is Hygeia Healthcare Holdings Co's Research & Development too high?
Hygeia Healthcare Holdings Co's current Research & Development is €0.0 Mil. Overall, Hygeia Healthcare Holdings Co has a GF Score™ of 74/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Hygeia Healthcare Holdings Co's Research & Development compare to HCA and THC?
Hygeia Healthcare Holdings Co's Research & Development of €0.0 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Healthcare Providers & Services company?
A good Research & Development depends on the Healthcare Providers & Services industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Hygeia Healthcare Holdings Co and its competitors. Hygeia Healthcare Holdings Co's current Research & Development is €0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hygeia Healthcare Holdings Co stock overvalued right now?
Based on GuruFocus' analysis, Hygeia Healthcare Holdings Co (STU:50I) is currently considered Possible Value Trap. The stock's GF Value™ is €2.43, compared to a current price of €1.06 — trading 56.4% below its estimated fair value. The current Research & Development is €0.0 Mil. Hygeia Healthcare Holdings Co's overall GF Score™ is 74/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Hygeia Healthcare Holdings Co (STU:50I), the current Research & Development is €0.0 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Hygeia Healthcare Holdings Co (STU:50I) Overvalued in 2026?

Based on GuruFocus' analysis, Hygeia Healthcare Holdings Co stock appears to be undervalued. The current stock price of €1.06 is trading 56.4% below its estimated GF Value™ of €2.43. GuruFocus considers Hygeia Healthcare Holdings Co to be Possible Value Trap.

Key valuation signals for STU:50I:

  • Research & Development: €0.0 Mil
  • GF Value™: €2.43 vs. price of €1.06 (56.4% below fair value)
  • GF Score™: 74/100 with 7 warning signs

No single metric tells the full story. See the STU:50I stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Hygeia Healthcare Holdings Co Business Description

Other Exchanges 06078:Hong Kong
Address 38 Yuanshen Road, Unit 1605/1606 ,Building 1, Fuyuan Zhidi Square, Pudong New Area, Shanghai, CHN
Hygeia Healthcare Holdings Co Ltd is an investment holding company mainly engaged in providing healthcare services through wholly owned, private, for-profit hospitals that are variable interest entities owned by the Group in the PRC. The Group mainly engages in the hospital business. Its segments include the inpatient services segment, which generates maximum revenue, and includes the provision of consultation services, provision of inpatient healthcare services, and sale of pharmaceutical products. The outpatient services segment includes the provision of consultation services and sale of pharmaceutical products. The others segment consists of a series of different services and products offering to customers, mainly including the radiotherapy center service.
74GF Score

Get the complete analysis for STU:50I

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.06
Price
€2.43
GF Value